EyePoint Announces 53% Workforce Reduction After Phase 3 LUCIA Trial Misses Primary Endpoint in Wet AMD

EyePoint announced a strategic prioritization plan following topline results from the Phase 3 LUCIA trial of DURAVYU in wet AMD, which did not meet its primary endpoint of non-inferiority despite meeting key secondary endpoints including reduction in treatment burden, supplement-free rates, anatomic control, and safety with redosing. The Board approved a plan to reduce the workforce by approximately 53%, conclude the pivotal Phase 3 wet AMD trials early, and refocus resources on the DURAVYU program in diabetic m...